Frank Torti - 23 May 2024 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+67,000		$0.000000	67,000	23 May 2024	Common Shares	67,000	$3.28	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2	The option is fully vested and exercisable as of the date of the grant.